相关实验视频
Updated: Jun 27, 2025

06:40
The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management
Published on: June 29, 2019
6.6K
泰戈普拉赞在功能性消化不良患者中的有效性:一个前性,多中心,单臂研究
Cheal Wung Huh1, Young Hoon Youn2, Da Hyun Jung3
1Department of Internal Medicine, Yongin Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
Journal of neurogastroenterology and motility
|May 6, 2024
概括
泰戈普拉桑是一种与竞争的酸阻断剂 (P-CAB),在8周内有效地缓解了86.7%的患者的功能性消化不良 (FD) 症状. 这种P-CAB证明了治疗FD的良好的安全性和有效性.
科学领域:
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 功能性消化不良症 (FD) 通常用诸如质子抑制剂 (PPI) 等酸抑制药物治疗.
- 竞争性酸阻断剂 (P-CABs) 对FD的有效性在很大程度上仍未确立.
- 这项研究调查了P-CAB,Tegoprazan的FD治疗疗效和安全性.
研究的目的:
- 通过使用"罗马四号标准"来评估对被诊断患有功能性消化不良 (FD) 的患者的泰戈普拉桑 (50毫克每天一次) 的疗效和安全性.
- 为了评估FD患者的症状缓解和生活质量改善,FD患者接受了Tegoprazan治疗.
- 为了确定FD亚型或Helicobacter pylori状态是否会影响tegoprazan的疗效.
主要方法:
- 一个前性的多中心临床试验,涉及173名患有FD的患者.
- 患者每天接受泰戈普拉赞50毫克,持续8周.
- 消化不良症状和生活质量是使用Nepean消化不良指数-韩国 (NDI-K) 和GERD与健康相关的生活质量 (GERD-HRQL) 尺度来衡量的.
主要成果:
- 86.7%的患者在8周和74.6%的患者在4周后获得了令人满意的症状缓解.
- 与基线相比,NDI-K和GERD-HRQL得分有显著改善.
- 泰戈普拉赞的疗效在不同的FD亚型和H. pylori状态中是一致的,在重叠的FD/GERD病例中效果更强. 没有报告任何严重的不良事件.
结论:
- 泰戈普拉桑 (50毫克) 每天服用一次,是功能性消化不良的有效治疗方法.
- 该P-CABtegoprazan提供了令人满意的症状缓解,并改善了FD患者的生活质量.
- 泰戈普拉桑是一种安全有效的选择,用于管理FD症状.
相关概念视频
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
113
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
113
Peptic Ulcer Disease IV: Management
89
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
89
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
249
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
249
Drugs for Treatment of Constipation-Predominant IBS
160
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
160
Gastroesophageal Reflux Disease II: Clinical Features and Management
72
Gastroesophageal reflux disease, or GERD, is a persistent medical condition that affects many individuals worldwide. Its clinical manifestations can vary greatly, making diagnosis and management challenging for healthcare professionals. The following is a comprehensive overview of the clinical manifestations, assessment, and management strategies for GERD.
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
72
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
309
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
309

